These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22079973)

  • 1. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
    Colson P; Purgus R; Borentain P; Gérolami R
    J Clin Virol; 2012 Feb; 53(2):178-80. PubMed ID: 22079973
    [No Abstract]   [Full Text] [Related]  

  • 2. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
    Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
    J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
    Colson P; Gérolami R
    J Infect Dis; 2011 May; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
    Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
    J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
    J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
    Belfrage AK; Abdurakhmanov E; Kerblom E; Brandt P; Oshalim A; Gising J; Skogh A; Neyts J; Danielson UH; Sandström A
    Bioorg Med Chem; 2016 Jun; 24(12):2603-20. PubMed ID: 27160057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
    Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
    Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
    Ehrenberg AE; Schmuck B; Anwar MI; Gustafsson SS; Stenberg G; Danielson UH
    J Enzyme Inhib Med Chem; 2014 Dec; 29(6):868-76. PubMed ID: 24517372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S; Vermehren J; Forestier N; Welker MW; Grigorian N; Füller C; Perner D; Zeuzem S; Sarrazin C
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.
    Morsica G; Bagaglio S; Uberti-Foppa C; Galli L; Lazzarin A
    J Acquir Immune Defic Syndr; 2009 May; 51(1):106-8. PubMed ID: 19390331
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.
    Holland-Staley CA; Kovari LC; Golenberg EM; Pobursky KJ; Mayers DL
    Arch Virol; 2002 Jul; 147(7):1385-406. PubMed ID: 12111414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.
    Besse B; Coste-Burel M; Bourgeois N; Feray C; Imbert-Marcille BM; André-Garnier E
    J Virol Methods; 2012 Oct; 185(1):94-100. PubMed ID: 22728274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.
    Vallet S; Gouriou S; Nousbaum JB; Legrand-Quillien MC; Goudeau A; Picard B
    J Med Virol; 2005 Apr; 75(4):528-37. PubMed ID: 15714495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.
    Tong X; Chase R; Skelton A; Chen T; Wright-Minogue J; Malcolm BA
    Antiviral Res; 2006 Jun; 70(2):28-38. PubMed ID: 16448708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors.
    Ferraro D; Urone N; Di Marco V; Craxì A
    Infect Genet Evol; 2014 Apr; 23():80-5. PubMed ID: 24508244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.